These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33559375)

  • 21. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.
    Nadkarni NK; Tudorascu D; Campbell E; Snitz BE; Cohen AD; Halligan E; Mathis CA; Aizenstein HJ; Klunk WE
    J Gerontol A Biol Sci Med Sci; 2019 Oct; 74(11):1753-1760. PubMed ID: 30957843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
    Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau PET in Alzheimer disease and mild cognitive impairment.
    Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
    Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting conversion from mild cognitive impairment to Alzheimer's disease using brain
    Mitolo M; Stanzani-Maserati M; Capellari S; Testa C; Rucci P; Poda R; Oppi F; Gallassi R; Sambati L; Rizzo G; Parchi P; Evangelisti S; Talozzi L; Tonon C; Lodi R; Liguori R
    Neuroimage Clin; 2019; 23():101843. PubMed ID: 31071594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroanatomical correlates of awareness of illness in patients with amnestic mild cognitive impairment who will or will not convert to Alzheimer's disease.
    Spalletta G; Piras F; Piras F; Sancesario G; Iorio M; Fratangeli C; Cacciari C; Caltagirone C; Orfei MD
    Cortex; 2014 Dec; 61():183-95. PubMed ID: 25481475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining neuropsychological and structural neuroimaging indicators of conversion to Alzheimer's disease in amnestic mild cognitive impairment.
    Venneri A; Gorgoglione G; Toraci C; Nocetti L; Panzetti P; Nichelli P
    Curr Alzheimer Res; 2011 Nov; 8(7):789-97. PubMed ID: 22175662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years.
    Bradfield NI; Ellis KA; Savage G; Maruff P; Burnham S; Darby D; Lautenschlager NT; Martins RN; Masters CL; Rainey-Smith SR; Robertson J; Rowe C; Woodward M; Ames D
    Alzheimer Dis Assoc Disord; 2018; 32(3):190-196. PubMed ID: 29561277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy.
    Wu KY; Lin KJ; Chen CH; Chen CS; Liu CY; Huang SY; Yen TC; Hsiao IT
    Brain Behav; 2018 Jul; 8(7):e01016. PubMed ID: 29927088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A biomarker study in long-lasting amnestic mild cognitive impairment.
    Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
    Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
    Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
    JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of mild cognitive impairment tending to convert into Alzheimer's disease or dementia with Lewy bodies: A follow-up study in a memory clinic.
    Kondo D; Ota K; Kasanuki K; Fujishiro H; Chiba Y; Murayama N; Sato K; Hirayasu Y; Arai H; Iseki E
    J Neurol Sci; 2016 Oct; 369():102-108. PubMed ID: 27653873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.
    Skouras S; Falcon C; Tucholka A; Rami L; Sanchez-Valle R; Lladó A; Gispert JD; Molinuevo JL
    Neuroimage Clin; 2019; 22():101777. PubMed ID: 30913531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.